Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke
CEO and Managing Director, Steven Yatomi-Clarke, held an investor briefing with Reach Markets where he discussed Prescient’s portfolio of assets and the list of top-tier partnerships collaborating on their developments.
During this session, Steven discussed:
- Our broad portfolio of well advanced assets developed with world-leading partners including Yale, UPenn, Oxford, Moffitt & Peter MacCallum.
- Our two first-in-class targeted therapies PTX-100 and PTX-200, currently in clinical development and showing encouraging activity.
- Our two next generation cell therapy platform technologies – OmniCAR and CellPryme.
Recorded on 8th November 2023 (AEST)
Featured Speaker
Steven Yatomi-Clarke
CEO and Managing Director
Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development.
Previously, Steven had a distinguished career as an investment banker specialising in the life sciences sector, where he was consistently one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments. In particular, Steven leveraged his combined backgrounds in science and finance to identify undervalued and unlikely opportunities and structure deals for the mutual benefit of companies and investors.
Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, both from the University of Melbourne. He has been a collaborator on various immunotherapy research projects.
